Early versus deferred standard androgen suppression therapy for advanced hormone-sensitive prostate cancer.

CONCLUSIONS: Early AST probably extends time to death of any cause and time to death from prostate cancer. It may slightly decrease the rate of skeletal events. Rates of serious adverse events and quality of life may be similar. It may increase fatigue and may increase the risk of heart failure. Better quality trials would be particularly important to better understand the outcomes related to possible treatment-related harm, for which we only found low-certainty evidence.
PMID: 31194882 [PubMed - as supplied by publisher]

Source: Cochrane Database of Systematic Reviews - June 10, 2019 Category: General Medicine Authors: Kunath F, Jensen K, Pinart M, Kahlmeyer A, Schmidt S, Price CL, Lieb V, Dahm P Tags: Cochrane Database Syst Rev Source Type: research